Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2008-01-08
2008-01-08
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S175000, C514S223200, C514S223500, C514S381000, C514S423000, C514S471000
Reissue Patent
active
10721020
ABSTRACT:
A method of treatment using a compound of Formula I:wherein:R1is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;R2is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;R3is hydrogen or lower alkyl of up to 6 carbon atoms;R4is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4together with R5can represent —CH2—O—;X is a valency bond, —CH2, oxygen or sulfur;Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl;R5and R6are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; orR5and R6together represent methylenedioxy;or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.
REFERENCES:
patent: 4503067 (1985-03-01), Wiedemann et al.
patent: 4888179 (1989-12-01), Appelgren et al.
patent: 5308862 (1994-05-01), Ohlstein
patent: 5312828 (1994-05-01), Finkelstein et al.
patent: 5760069 (1998-06-01), Lukas-Laskey et al.
patent: 5902821 (1999-05-01), Lukas-Laskey et al.
patent: 1259071 (1989-09-01), None
patent: 696 02 424 (1997-11-01), None
patent: 0 808 162 (1997-11-01), None
Bristol Meyers Squibv.Ben Venue Labs.,246 F .3d 1368 (Fed. Cir. 2001).
Rapoportv.Dement, 254 F.3d 1053 (Fed. Cir.2001).
Jansenv.Rexall Sundown, Inc.,342 F.3d 1329, 1333-34 (Fed. Cir. 2003).
Glaxo Group Ltd.v.Teva Pharma, Inc.,2004 U.S. Dist. LEXIS 16750, at *56-57 (D. Del. 2004).
Swedberg, Karl et al., “Prolongation of Survival in Congestive Cardiomyopathy by Beta-Receptor Blockade,” Lancet 1374-1376 (Jun. 30, 1979).
Prichard, B.N.C. and Tomlinson, B., “Choice of Antihypertensive Drug Therapy,” Am Heart J; 114 (4): 1030-40 (Oct. 1987).
Das Gupta et al., “Improvement in congestive heart failure following chronic therapy with a new vasodilating betablocker Carvedilol,” Circulation, vol. 80, No. 4, Suppl. 2, II -117 (1989).
DiBanco, Robert et al., “A Comparison of Oral Milrinone, Digoxin, and Their Combination in the Treatment of Patients with Chronic Heart Failure,” New England J. Med., vol. 320, No. 11, 677-683 (Mar. 16, 1989).
Das Gupta, P. et al., “Value of carvedilol in congestive heart failure secondary to coronary artery disease,” American Journal of Cardiology, vol. 66, No. 15, pp. 1118-1123, (Nov. 1, 1990).
Krukemyer, J., “Use of Beta-Adrenergic Blocking Agents in Congestive Heart Failure,” Clin Pharm 9(11): 853-63 (Nov. 1990).
Strein, K. and Sponer, G, “Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule,” Z Kardiol 79 Suppl. 3, pp. 89-98 (1990).
Das Gupta, P. et al., “The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.,” J Cardiovasc Pharmacol, vol. 18, Suppl. 7, pp. S 12-16 (1991).
Di Lenarda, Andrea, “Acute Hemodynamic Effects of Carvedilol Versus Metoprolol in Idiopathic Dilated Cardiomyopathy.,” Abstract —JACC vol. 17(2), 142A (Feb. 1991).
Hamburger, S.A. et al., “Carvedilol (Kredex®) reduces infarct size in a canine model of acute myocardial infarction,” Pharmacology, vol. 43, pp. 113-120 (1991).
Ruffolo, R. et al., “Carvedilol (Kredex®): A Novel Multiple Action Cardiovascular Agent,” Drugs of Today 27(7): 465-492 (1991).
Bristow, M.R. et al., “Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes,” Clinical Investig 70 Suppl 1: S105-13 (1992).
Das Gupta, P. et al., “Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease?” J. Cardiovasc Pharmacol, vol. 19, Suppl. I, pp. S62-7 (1992).
De Cree, J. et al., “Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers,” Int J Clin Pharmacol Res., vol. 12, No. 4, pp. 159-163 (1992).
Feuerstein, G.Z. et al., “Myocardial protection with Carvedilol,” J Cardiovasc Pharmacol, vol. 19, Suppl. 1, pp. S138-41 (1992).
Senior, R.; Müller-Beckmann, B., Das Gupta, P., van der Does, R. and Lahiri, A. “Effects of carvedilol on ventricular arrhythmias,” J Cardiovasc Pharmacol 19 Suppl. 1:S117-21 (1992).
Sponer, G. et al., “Vasodilatory action of Carvedilol,” J Cardiovasc Pharmacol 19 Suppl 1:S5-11 (1992).
Bristow, M.R., “Pathophysiologic and Pharmacologic Rationales for Clinical Management of Chronic Heart Failure with Beta-Blocking Agents,” Am J Cardiol 71(9):12C-22C (1993).
Cheng, H.-Y., et al., “Physical chemical investigation of antioxidant properties of carvedilol a cadioprotective drug,” International Congress Series No. 1058, Frontiers of reactive oxygen species in biology and medicine, 349-350 (1994).
Feuerstein, G.Z. et al., “Myocardiol protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity,” J Hypertens, vol. 11, No. Suppl. 4, pp. S41-8 (Jun. 1993).
Fowler, M.B., “Controlled trials with beta blockers in heart failure: metoprolol as the prototype,” Am J Cardiol vol. 71, No. 9, pp. 45C-53C (Mar. 25, 1993).
Kelly, David T., “Carvedilol in Heart Failure,” Cardiology 82(suppl 3):45-49 (1993).
Krum, Henry et al., “Controlled Clinical Trials in Heart Failure I: Beta-Blockers,” JACC vol. 21, No. 2: 114A, Abstract 725-1 (Feb. 1993).
Lessem, J. N. and Lukas, M.A., “Development of a multiaction beta blocker. Scientific challenges and regulatory needs,” Cardiology vol. 82, Suppl 3, pp. 50-58 (1993).
McTavish, Donna, et al., “Carvedilol: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy,” Drugs, vol. 45, No. 2, pp. 232-258 (Feb. 1993).
Ohlstein, E.H. et al., “Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury,” Proc Natl. Acad. Sci U.S.A., vol. 90, No. 13, pp. 6189-6193 (Jul. 1993).
Olsen, Stephanie et al., “Controlled Clinical Trials in Heart Failure I: Beta Blockers,” JACC vol. 21, No. 2:141A, Abstract 725-2 (Feb. 1993).
Metra, M. et al., “Effects of acute and chronic Carvedilol on resting and exercise hemodynamics of patients with idiopathic cardiomyopathy,” JACC vol. 21, No. 2:141A, Abstract 725-3 (Feb. 1993).
Rosendorff, C., “Beta-blocking agents with vasodilator activity,” J Hypertens Suppl vol. 11, No. 4, pp. S37-40 (Jun. 1993).
Ruffolo, R.R. et al., “Preclinical and clinical pharmacology of Carvedilol,” J Hum Hypertens vol. 7 Suppl. 1, pp. S2-15 (Feb. 1993).
Waagstein, Finn, “Beneficial Effects of metoprolol in idiopathic dilated cardiomyopathy,” Lancet, vol. 342. 1441-46 (Dec. 11, 1993).
Unknown, “SB to file seven NDAs, launch Havrix hepatitis A vaccine in 1995; No major drugs come off patent through 2000: Genomics work as synergy with diagnostics—BBS,” F-C-D Reports—“The Pink Sheet” , vol. 56, No. 51, pp. 17-18 (Dec. 19, 1994).
CIBIS Investigators and Committees, “A Randomized Trial of Beta-Blockade in Heart Failure—The Cardiac Insufficiency Bisoprolol Study (CIBIS),” Circulation, vol. 90(4), 1765-1773 (1994).
Doughty, R.N. et al., “Beta-
Lukas-Laskey Mary Ann
Ruffolo, Jr. Robert
Shusterman Neil Howard
Sponer Gisbert
Strein Klaus
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
SB Pharmco Puerto Rico Inc.
Weddington Kevin E.
LandOfFree
Method of treatment for decreasing mortality resulting from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for decreasing mortality resulting from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for decreasing mortality resulting from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3957748